CHICAGO--(BUSINESS WIRE)--Tempus, a technology company leading the adoption of AI to advance precision medicine, today highlighted results of the Articulate Pro study, published in Nature Digital Medicine, evaluating the use of AI to assist pathologists in prostate biopsy reporting. The study was a real-world evaluation of the Paige Prostate Suite, an integral part of the Tempus intelligent diagnostics ecosystem, and its integration into routine clinical workflows. AI-assisted review supported
Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service
